A composition for inhibiting corrosion of a metal is provided. The corrosion inhibitor composition comprises 5-amino-2-mercaptobenzimidazole. The corrosion inhibitor composition can also comprise a 2-mercaptobenzimidazole derivative selected from the group consisting of 2-mercapto-5-methylbenzimidazole, 5-Ethoxy-2-mercaptobenzimidazole, 5-(difluoromethoxy)-2-mercapto-1H-benzimidazole 1-Methyl-1H-benzimidazole-2-thiol and 2-mercapto-5-nitrobenzimidazole. The corrosion inhibitor composition outperforms many other sulfur-containing corrosion inhibitors in kettle testing.

A composition for inhibiting corrosion of a metal is provided. The corrosion inhibitor composition comprises 5-amino-2-mercaptobenzimidazole. The corrosion inhibitor composition can also comprise a 2-mercaptobenzimidazole derivative selected from the group consisting of 2-mercapto-5-methylbenzimidazole, 5-Ethoxy-2-mercaptobenzimidazole, 5-(difluoromethoxy)-2-mercapto-1H-benzimidazole 1-Methyl-1H-benzimidazole-2-thiol and 2-mercapto-5-nitrobenzimidazole. The corrosion inhibitor composition outperforms many other sulfur-containing corrosion inhibitors in kettle testing.

The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target proteins; i.e. via degradation of a target protein/target proteins by the cullin-RING ubiquitin ligase (CRL). Such target protein/target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and/or neurological disorder. The invention further relates to a method for identifying/obtaining and/or testing a compound able to induce ubiquitination of a target protein/target proteins. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds. Particularly, the compounds of the present invention may degrade proteins associated with cancer, metabolic disorder, infectious disease and/or neurological disorder. Furthermore, the present invention relates the compounds for use as a medicament, such as for use in treating cancer, metabolic disorder, infectious disease and/or neurological disorder and to a method for treating a disease, such as cancer, metabolic disorder, infectious disease and/or neurological disorder, comprising administering the compound of the present invention.

The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target proteins; i.e. via degradation of a target protein/target proteins by the cullin-RING ubiquitin ligase (CRL). Such target protein/target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and/or neurological disorder. The invention further relates to a method for identifying/obtaining and/or testing a compound able to induce ubiquitination of a target protein/target proteins. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds. Particularly, the compounds of the present invention may degrade proteins associated with cancer, metabolic disorder, infectious disease and/or neurological disorder. Furthermore, the present invention relates the compounds for use as a medicament, such as for use in treating cancer, metabolic disorder, infectious disease and/or neurological disorder and to a method for treating a disease, such as cancer, metabolic disorder, infectious disease and/or neurological disorder, comprising administering the compound of the present invention.

The present invention relates to hydrosoluble compounds derived from benzimidazole represented by general formula I:

##STR00001##

wherein: Y.sup.1 e Y.sup.2 are independently O or S, and at least one of Y.sup.1 and Y.sup.2 is O; R.sup.1 and R.sup.2 are independently hydrogen or a cation, both are hydrogen or both are cations; R.sup.3 is a C1-4 alkyl; R.sup.4 and R.sup.5 are independently halogen or a —OR.sup.6 alkoxide; R.sup.6 is C6-C10 aryl linked in 5- or 6-position of benzimidazole nucleus.

The present invention relates to hydrosoluble compounds derived from benzimidazole represented by general formula I:

##STR00001##

wherein: Y.sup.1 e Y.sup.2 are independently O or S, and at least one of Y.sup.1 and Y.sup.2 is O; R.sup.1 and R.sup.2 are independently hydrogen or a cation, both are hydrogen or both are cations; R.sup.3 is a C1-4 alkyl; R.sup.4 and R.sup.5 are independently halogen or a —OR.sup.6 alkoxide; R.sup.6 is C6-C10 aryl linked in 5- or 6-position of benzimidazole nucleus.

The present invention generally relates to methods and compounds for preventing metal corrosion. More specifically, the method comprises contacting a hydrocarbon-containing liquid with a composition in an effective amount to prevent metal corrosion.

The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.

Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.